BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Salvia R, Casciani F, Sereni E, Bassi C. Pancreatic cancer – What's next? Presse Med 2019;48:e187-97. [PMID: 30878338 DOI: 10.1016/j.lpm.2019.02.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Brugel M, Letrillart L, Evrard C, Thierry A, Tougeron D, El Amrani M, Piessen G, Truant S, Turpin A, Christelle d'Engremont, Roth G, Hautefeuille V, Regimbeau JM, Williet N, Schwarz L, Di Fiore F, Borg C, Doussot A, Lambert A, Moulin V, Trelohan H, Bolliet M, Topolscki A, Ayav A, Lopez A, Botsen D, Piardi T, Carlier C, Bouché O. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: a French comprehensive multicentre ambispective observational cohort study (CAPANCOVID). European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.01.040] [Reference Citation Analysis]
3 Liu XJ, Yang T, Shi X, Xiao BH, An LY, Zheng SY, Qi YX, Sun DL. Systematic appraisal of guidelines for the diagnosis of pancreatic cancer. Gland Surg 2021;10:1487-98. [PMID: 33968700 DOI: 10.21037/gs-20-676] [Reference Citation Analysis]
4 Fan P, Ma J, Jin X. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Biochemical and Biophysical Research Communications 2018;505:830-6. [DOI: 10.1016/j.bbrc.2018.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
5 Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) 2020;12:E3866. [PMID: 33371464 DOI: 10.3390/cancers12123866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Liu J, Hu L, Zhou B, Wu C, Cheng Y. Development and validation of a novel model incorporating MRI-based radiomics signature with clinical biomarkers for distinguishing pancreatic carcinoma from mass-forming chronic pancreatitis. Transl Oncol 2022;18:101357. [PMID: 35114568 DOI: 10.1016/j.tranon.2022.101357] [Reference Citation Analysis]
7 Radi I, Samaha R, El Hajj J, Samaha H, Kourie HR. Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care? Future Oncol 2021;17:229-33. [PMID: 33305614 DOI: 10.2217/fon-2020-0836] [Reference Citation Analysis]
8 Huguet F, Rivin Del Campo E, Orthuon A, Mornex F, Bessières I, Guimas V, Vendrely V. Radiation therapy of pancreatic cancers. Cancer Radiother 2021:S1278-3218(21)00199-2. [PMID: 34953706 DOI: 10.1016/j.canrad.2021.08.010] [Reference Citation Analysis]
9 Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.Oncologist. 2020;25:e1701-e1710. [PMID: 32886823 DOI: 10.1634/theoncologist.2020-0577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Taibi A, Jacques J, Durand Fontanier S, Charissoux A, Bardet SM, Christou N, Fredon F, Valleix D, Mathonnet M. Long-term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review. Clin Case Rep. 2019;7:2092-2101. [PMID: 31788258 DOI: 10.1002/ccr3.2429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbrielli A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, Melisi D. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Ther Adv Med Oncol. 2020;12:1758835920947969. [PMID: 33403007 DOI: 10.1177/1758835920947969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Palmieri LJ, Coriat R. 18F-FDG PET/CT in pancreatic adenocarcinoma: On the edge of a paradigm shift? Diagn Interv Imaging 2019;100:731-3. [PMID: 31780041 DOI: 10.1016/j.diii.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol 2020;32:356-63. [PMID: 32541325 DOI: 10.1097/CCO.0000000000000639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, Jamieson NB, Lamarca A, van Santvoort HC, Molenaar IQ, Valle JW, Roberts KJ. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021;47:2248-55. [PMID: 34034941 DOI: 10.1016/j.ejso.2021.04.031] [Reference Citation Analysis]
15 Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol 2021;45:101607. [PMID: 33662776 DOI: 10.1016/j.clinre.2020.101607] [Reference Citation Analysis]
16 Manhal K, Gaetan M, Thierry D, Baudouin M. A rare case of adenocarcinoma of an ectopic pancreas: A case report. International Journal of Surgery Case Reports 2022;94:107061. [DOI: 10.1016/j.ijscr.2022.107061] [Reference Citation Analysis]
17 Belyaev O, Bösch F, Brunner M, Müller-debus CF, Radulova-mauersberger O, Wellner UF, Grützmann R, Keck T, Werner J, Witzigmann H, Uhl W. Von der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie konsentierte Operationsindikationen beim duktalen Pankreasadenokarzinom. Zentralbl Chir 2020;145:354-64. [DOI: 10.1055/a-1161-9501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Perri G, Prakash LR, Katz MHG. Response to Preoperative Therapy in Localized Pancreatic Cancer. Front Oncol 2020;10:516. [PMID: 32351893 DOI: 10.3389/fonc.2020.00516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kpossou AR, Gbessi DG, Gnangnon FHR, Ba Boukari MM, Vignon RK, Sokpon CNDM, Sehonou J. [Cancers of the pancreas at the National Hospital and University Center of Cotonou: epidemiological, diagnostic, therapeutic and prognostic features]. Pan Afr Med J 2021;39:18. [PMID: 34394809 DOI: 10.11604/pamj.2021.39.18.26261] [Reference Citation Analysis]
21 Zhou W, Li SY, Jiang H, Gao L, Li J, Kong XY, Yang L, Fang AQ, Jin ZD, Wang KX. Optimal number of needle passes during EUS-guided fine-needle biopsy of solid pancreatic lesions with 22G ProCore needles and different suction techniques: A randomized controlled trial. Endosc Ultrasound 2021;10:62-70. [PMID: 33586696 DOI: 10.4103/EUS-D-20-00147] [Reference Citation Analysis]
22 Liu H, Shi Y, Qian F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv Drug Deliv Rev 2021;172:37-51. [PMID: 33705881 DOI: 10.1016/j.addr.2021.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
24 Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572] [Reference Citation Analysis]
25 Liu C, Yu H, Hou YH, Gao ZL, Zhang YJ. Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanced Pancreatic Cancer. Pak J Med Sci 2022;38:118-22. [PMID: 35035411 DOI: 10.12669/pjms.38.1.4150] [Reference Citation Analysis]
26 Tong T, Tian L, Deng M, Liu Y, Yang Y, Yin H, Long X, Pan S, Yang Z, Luo W, Nie K, Meng X, Xiao M, Wu X, Zhang C, Wang X. Comparison between modified wet suction and dry suction technique for endoscopic ultrasound-guided fine-needle biopsy in pancreatic solid lesions. J Gastroenterol Hepatol 2021;36:1663-9. [PMID: 33295070 DOI: 10.1111/jgh.15371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Williet N, Petrillo A, Roth G, Ghidini M, Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F, Taieb J, Phelip JM. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers (Basel) 2021;13:2797. [PMID: 34199796 DOI: 10.3390/cancers13112797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sheetz KH, Dimick JB, Nathan H. Centralization of High-Risk Cancer Surgery Within Existing Hospital Systems. J Clin Oncol 2019;37:3234-42. [PMID: 31251691 DOI: 10.1200/JCO.18.02035] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 10.3] [Reference Citation Analysis]
30 Olivier R, Randrian V, Tougeron D, Saurin JC. Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome. Cancers (Basel) 2021;13:3505. [PMID: 34298719 DOI: 10.3390/cancers13143505] [Reference Citation Analysis]
31 Daniluk J, Daniluk U, Rogalski P, Dabrowski A, Swidnicka-Siergiejko A. Microbiome-Friend or Foe of Pancreatic Cancer? J Clin Med 2021;10:5624. [PMID: 34884327 DOI: 10.3390/jcm10235624] [Reference Citation Analysis]
32 Vary A, Lebellec L, Di Fiore F, Penel N, Cheymol C, Rad E, El Hajbi F, Lièvre A, Edeline J, Bimbai AM, Le Deley MC, Turpin A. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Ther Adv Med Oncol 2021;13:17588359211029825. [PMID: 34349842 DOI: 10.1177/17588359211029825] [Reference Citation Analysis]
33 Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369-382. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Piquemal D, Noguier F, Pierrat F, Bruno R, Cros J. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Cancers (Basel) 2020;12:E3204. [PMID: 33143297 DOI: 10.3390/cancers12113204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Dallongeville A, Corno L, Silvera S, Boulay-coletta I, Zins M. Initial Diagnosis and Staging of Pancreatic Cancer Including Main Differentials. Seminars in Ultrasound, CT and MRI 2019;40:436-68. [DOI: 10.1053/j.sult.2019.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Wei M, Gu B, Song S, Zhang B, Wang W, Xu J, Yu X, Shi S. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Front Oncol 2021;11:650266. [PMID: 34055620 DOI: 10.3389/fonc.2021.650266] [Reference Citation Analysis]
37 Collard M, Voron T, Svrcek M, Ahmed O, Balladur P, Hor T, André T, Paye F. Para-aortic lymph node metastasis detected intraoperatively by systematic frozen section examination in pancreatic head adenocarcinoma: is resection improving the prognosis? HPB (Oxford) 2020;22:1604-12. [PMID: 32179009 DOI: 10.1016/j.hpb.2020.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ocaña J, Sanjuanbenito A, García A, Molina JM, Lisa E, Mendía E, Saavedra C, Lobo E. Relevance of positive resection margins in ductal pancreatic adenocarcinoma and prognostic factors. Cir Esp (Engl Ed) 2020;98:85-91. [PMID: 31395275 DOI: 10.1016/j.ciresp.2019.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Jeune F, Coriat R, Prat F, Dousset B, Vaillant JC, Gaujoux S. Pancreatic cancer surgical management. Presse Med 2019;48:e147-58. [PMID: 30905395 DOI: 10.1016/j.lpm.2019.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
40 Zhang Q, Lu J, Jia M, Ma Y, Sun M, Chen X, Ma X, Yang Y, Kang J, Zhang X, Paiella S, Katz MHG, Tsuchida K, Schattner M, Du S. Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist. Ann Transl Med 2021;9:1088. [PMID: 34423000 DOI: 10.21037/atm-21-2644] [Reference Citation Analysis]
41 Mas L, Lupinacci RM, Cros J, Bachet JB, Coulet F, Svrcek M. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights. Int J Mol Sci 2021;22:6756. [PMID: 34201897 DOI: 10.3390/ijms22136756] [Reference Citation Analysis]
42 Ulusakarya A, Teyar N, Karaboué A, Haydar M, Krimi S, Biondani P, Gumus Y, Chebib A, Almohamad W, Morère JF. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2019;98:e15341. [PMID: 31008993 DOI: 10.1097/MD.0000000000015341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
43 Lee JC, Shin DW, Park H, Kim J, Youn Y, Kim JH, Kim J, Hwang JH. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointest Endosc 2020;92:1044-1052.e1. [PMID: 32084409 DOI: 10.1016/j.gie.2020.02.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
44 Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Reference Citation Analysis]
45 Brugel M, Bouché O, Kianmanesh R, Teuma L, Tashkandi A, Regimbeau JM, Pessaux P, Royer B, Rhaiem R, Perrenot C, Neuzillet C, Piardi T, Deguelte S. Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma. BMC Surg 2021;21:413. [PMID: 34876080 DOI: 10.1186/s12893-021-01409-7] [Reference Citation Analysis]
46 Luo Y. The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database. Clin Transl Oncol 2021. [PMID: 34219204 DOI: 10.1007/s12094-021-02671-0] [Reference Citation Analysis]
47 Marichez A, Turrini O, Fernandez B, Garnier J, Lapuyade B, Ewald J, Adam JP, Marchese U, Chiche L, Delpero JR, Laurent C. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity and R0 resection? A bi-centric French cohort study. HPB (Oxford) 2021:S1365-182X(21)00103-9. [PMID: 33933344 DOI: 10.1016/j.hpb.2021.04.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Peng C, Zhou D, Meng L, Cao Y, Zhang H, Pan Z, Lin C. The value of combined vein resection in pancreaticoduodenectomy for pancreatic head carcinoma: a meta-analysis. BMC Surg 2019;19:84. [PMID: 31286916 DOI: 10.1186/s12893-019-0540-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
49 Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol 2019;45:1770-7. [PMID: 31204168 DOI: 10.1016/j.ejso.2019.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Seitz JF, Lepage C, François E; PRODIGE 35 Investigators/Collaborators. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. J Clin Oncol 2021;39:3242-50. [PMID: 34288696 DOI: 10.1200/JCO.20.03329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Fiore M, Taralli S, Trecca P, Scolozzi V, Marinelli L, Triumbari EKA, Caputo D, Angeletti S, Ciccozzi M, Coppola A, Greco C, Ippolito E, Calcagni ML, Coppola R, Ramella S. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Cancers (Basel) 2020;12:E2016. [PMID: 32717967 DOI: 10.3390/cancers12082016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
53 Tortajada P, Sauvanet A, Truant S, Regenet N, Souche R, Benoist S, Muscari F, Regimbeau JM, Gaujoux S, Cunha AS, Schwarz L, French-Achbt Working Group. Does Fungal Biliary Contamination after Preoperative Biliary Drainage Increase Postoperative Complications after Pancreaticoduodenectomy? Cancers (Basel) 2020;12:E2814. [PMID: 33007843 DOI: 10.3390/cancers12102814] [Reference Citation Analysis]
54 Pignon F, Turpin A, Hentic O, Coriat R, Salmon E, Baumgaertner I, Bertrand N, Lévy P, Rebours V, Hammel P, de Mestier L. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Pancreatology 2021:S1424-3903(21)00157-5. [PMID: 34090806 DOI: 10.1016/j.pan.2021.05.006] [Reference Citation Analysis]
55 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
56 Tijeras-Raballand A, Hilmi M, Astorgues-Xerri L, Nicolle R, Bièche I, Neuzillet C. Microbiome and pancreatic ductal adenocarcinoma. Clin Res Hepatol Gastroenterol 2021;45:101589. [PMID: 33607375 DOI: 10.1016/j.clinre.2020.101589] [Reference Citation Analysis]
57 Joret R, Matti N, Beck M, Michel B. Medication adherence and persistence among patients with non-small cell lung cancer receiving tyrosine kinase inhibitors and estimation of the economic burden associated with the unused medicines. J Oncol Pharm Pract 2021;:10781552211012452. [PMID: 33896267 DOI: 10.1177/10781552211012452] [Reference Citation Analysis]